Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Heart | Hematology | Thrombocytopenia | Thrombosis